Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis
NCT02618317 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2016-12-02
Summary
Background: Poor flow (PF) and catheter-related blood stream infections (CRBSI) are highly prevalent among CKD 5D patients with long-term central venous catheters. Heparin (H) catheter lock solutions are commonly used to maintain catheter patency, however PF and CRBSI incidence remains high. The purpose of this study was to evaluate two lock solutions on reduction of PF and CRBSI: one, a lock solution combining of the tetracycline antibiotic minocycline with the anticoagulant/chelation agent EDTA (M-EDTA) versus H; and other, trisodium citrate (C) versus H. M-EDTA and C were also evaluated as to their safety versus H.
Methods:As regards the pilot project, thirty CKD 5D patients on high-efficiency hemodialysis (blood flow rate = 350 ml/min) at the Integrated Centre of Nephrology (Guarulhos, Brazil) were randomized 1:1:1 to receive M-EDTA, C or H locks for 15 weeks. Lock solutions concentrations were M-EDTA 30 mg/ml/3 mg/ml, C 30% (C) and H 1,000 U/ml and both investigators and patients were blinded to treatment allocation. The primary end-point was a 10% reduction in HD blood flow rates (35ml). The frequency of CRBSI was recorded. Bleeding and lock solution-related adverse events were the primary safety end points. Logistic Regression was performed to evaluate differences in PF rates among the treatments (SPSS version 13.0, IBM, USA).
Based upon the pilot-study data, the clinical trials has being executed in order to verify whether the three lock solutions have the same performance or not.
Conditions
Interventions
- DRUG
-
Heparin Lock Solution
Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
- DRUG
-
Trissodium Citrate 30%
ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
- DRUG
-
Minocycline-EDTA 30 mg/ml - 3 mg/ml
ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
Sponsors & Collaborators
-
Fundação de Amparo à Pesquisa do Estado de São Paulo
collaborator OTHER_GOV -
University of Sao Paulo
lead OTHER
Principal Investigators
-
Marcus Luiz, MSc, PharmD · PhD student
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-07-31
- Primary Completion
- 2016-02-29
- Completion
- 2016-03-31
Countries
- Brazil
Study Locations
More Related Trials
-
The Impact of Different Citrate Concentrations as Locking Solutions on Development of Biofilm and Function of Hemodialysis Catheters
NCT03683563 ·Status: UNKNOWN ·Phase: NA
-
Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.
NCT03539718 ·Status: UNKNOWN ·Phase: PHASE4
-
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
NCT03627884 ·Status: COMPLETED ·Phase: PHASE4
-
Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections
NCT01483872 ·Status: TERMINATED ·Phase: PHASE3
-
The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients
NCT03470727 ·Status: COMPLETED ·Phase: NA
-
Methylene Blue for the Prevention of Hypotension During Hemodialysis
NCT05092165 ·Status: COMPLETED ·Phase: PHASE2
-
Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients
NCT00467311 ·Status: COMPLETED
-
Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.
NCT01229072 ·Status: SUSPENDED ·Phase: PHASE2/PHASE3
-
Role of Amlodipine in Reduction of CIN
NCT07291375 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction
NCT01218178 ·Status: COMPLETED
-
Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy
NCT00606827 ·Status: COMPLETED ·Phase: PHASE4
-
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
NCT07203287 ·Status: RECRUITING ·Phase: PHASE4
-
Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
NCT02106962 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Sodium Bicarbonate Solution in Decreasing the Incidence of Contrast Induced Nephropathy (CIN)
NCT00514150 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
NCT01093131 ·Status: WITHDRAWN ·Phase: PHASE4
-
Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate
NCT00312117 ·Status: COMPLETED ·Phase: PHASE3
-
Bicarbonate v Saline to Prevent Contrast Nephropathy
NCT00384995 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients
NCT03614741 ·Status: RECRUITING ·Phase: PHASE4
-
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
NCT06150742 ·Status: RECRUITING ·Phase: NA
-
Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction
NCT01160627 ·Status: COMPLETED ·Phase: NA
-
The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
NCT03627130 ·Status: COMPLETED ·Phase: PHASE2
-
Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients
NCT02470247 ·Status: COMPLETED ·Phase: NA
-
Renal Retention of Microbubbles
NCT01647464 ·Status: COMPLETED
-
Renoprotective Effects of Fluid Prophylaxis Strategies for Contrast Induced Nephropathy (CIN)
NCT00749827 ·Status: WITHDRAWN ·Phase: PHASE4
-
The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy
NCT00494637 ·Status: TERMINATED ·Phase: NA